60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals plans to stop enrollment in its severe babesiosis trial at 30 patients, versus the originally planned 33, and unblind the study; primary and secondary endpoint results are expected in January 2027. The DSMB recommended completing the planned enrollment but identified no safety issues and did not determine whether the study met its endpoints. The company also reported molecular cure in the first three patients in an expanded-access study and plans to seek an FDA pre-sNDA meeting in January 2027; any approval pathway remains subject to FDA review.

Analysis

This is a catalyst-timing change, not an efficacy signal: the DSMB did not establish that the trial met either endpoint, and the blinded 30-patient dataset may still produce imprecise estimates. The key near-term asymmetry for SXTP is that a positive January readout could validate a treatment niche, while a negative or ambiguous result leaves the separate refractory-disease case-report pathway dependent on FDA acceptance of sparse evidence and NAT clearance as a surrogate. The early-November expanded-access update is a small, uncontrolled data point—not independent confirmation of a treatment effect.

Commercial upside is difficult to underwrite before the addressable refractory population, treatment duration, pricing, and uptake are established. A further constraint is execution: the company discloses going-concern doubt and no manufacturing capacity, so even favorable data may increase financing and partnering needs rather than translate directly into near-term product economics. The proposed accelerated-approval route is conditional on FDA review; a requirement for additional controlled evidence would extend the timeline and capital burden.

The contrarian point: avoiding a year-long seasonal delay improves catalyst visibility, but does not improve the evidence quality. Treat SXTP as a high-binary, potentially financing-sensitive event rather than a de-risked regulatory story. A favorable readout is not enough if effect size, endpoint consistency, or FDA feedback disappoints.

Key Decisions for Investors

• Near term: avoid adding directional exposure solely on the enrollment decision. Monitor SXTP liquidity and financing disclosures; the company’s going-concern warning and lack of manufacturing capacity can make dilution a competing catalyst even if clinical news is favorable.
• November 2026: treat the two additional expanded-access screens as an alert, not a confirmatory catalyst. Reassess only after verifying the number evaluable, assay details, durability of molecular clearance, and clinical outcomes.
• January 2027: keep any event exposure small and explicitly binary. A thesis-supporting result requires clinically coherent primary and secondary endpoint outcomes, not merely a favorable molecular-clearance narrative; reduce exposure if the final analysis is inconclusive or FDA signals that a controlled trial is needed.
• Falsification / risk triggers: endpoint failure or weak separation, relapse after reported molecular clearance, FDA rejection of NAT clearance as a suitable surrogate or a demand for materially more data, and financing terms that materially dilute existing equity.